最新消息

2025 傑出生技產業獎 漢康生技勇奪傑出新創獎殊榮 漢康生技（HanchorBio Inc.）於8日下午出席 […]

專注於免疫腫瘤學創新生物藥開發的漢康-KY（7827）6月30日宣布，與上海復宏漢霖生物技術股份有限公司（以下 […]

HanchorBio Inc., a global biotechnology company dedicated to developing innovative immuno-medicines to address significant unmet medical needs in oncology and autoimmune diseases, has been awarded the 2025 Taiwan Biopharma Excellence Award at Biologics World Taiwan, hosted by IMAPAC. The company was also named “Company to Watch Out for in Taiwan”, recognizing its innovation, leadership, and growth potential in biologics development.This industry recognition highlights HanchorBio’s significant progress in advancing its proprietary Fc-Based Designer Biologics (FBDB™) platform and underlines the company’s potential as it prepares for its next phase of corporate growth, including an anticipated IPO in Taiwan.

1. 為何會創立漢康生技？2. 漢康生技創立的時間跟宗旨是？3. 目前為止，漢康生技已獲得哪些研發的成果或是募資上的成功？4. 漢康生技的願景是甚麼?5. 針對生物科技、醫療相關領域，漢康生技能為社會做些甚麼？6. 漢康生技所研發的藥物跟其他傳統藥物的最大區別跟優勢是？關鍵技術是？7. FBDB™是甚麼？特別之處是？它對研發上有哪些幫助？8. 預計受惠者的規模或是程度為何？9. 像這樣多種靶向模式的生物製劑，以重啟免疫系統來對抗疾病的機轉，是否能應用於其他疾病或醫學領域？

Dr. Liu was awarded on November 12, 2022, as part of the CABS 23rd Annual BioPacific Conference entitled, “Resilience and Ingenuity – Embracing Opportunities in a New Normal”. The theme this year reflects economic and supply chain turbulences that have presented both new challenges and opportunities for the life sciences and biopharmaceutical industries, despite ongoing COVID-19. For the past 24 years, CABS has been one of the largest and most active non-profit biopharmaceutical organizations in western United States.

At the SAPA conference, HanchorBio presented the company’s proprietary Fc-based designer biologics (FBDB™) platform led to biological products that targeting phagocytosis checkpoint blockade and incorporating both innate and adaptive immune responses to treat patients with cancer. During the conference, HanchorBio ended with dozens of one-on-one meetings with national and international partners and multiple possible leads for in-licensing, research collaborations, or commercial right out-licensing conducted by Dr. Yi Du (Sr. Director of Business Development). These discussions mainly focused on advancing science and innovation on the development of anti-tumor immunotherapies to eliminate tumor immune escape.